BMS-817399 / BMS - LARVOL DELTA

Identification of potential drug targets for vascular dementia and carotid plaques by analyzing underlying molecular signatures shared by them. (PubMed, Front Aging Neurosci) - "The drug-gene interaction analysis showed that four drugs (avacopan, CCX354, BMS-817399, and ASK-8007) could be potential drugs for VaD and carotid atherosclerotic plaques treatment. Collectively, these findings indicated that inflammatory and immune-related processes be a crucial common pathophysiological mechanism shared by VaD and carotid plaques. This study might provide new insights into common molecular mechanisms between VaD and carotid plaques and potential targets for the treatment."

Journal • Alzheimer's Disease • Atherosclerosis • Cardiovascular • CNS Disorders • Dementia • Dyslipidemia • Immunology • CD4

The discovery of CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis (J Med Chem) - "High affinity, functionally potent, urea-based antagonists of CCR1 have been discovered. Modulation of PXR transactivation has revealed the selective and orally bioavailable CCR1 antagonist BMS-817399 (29), which entered clinical trials for the treatment of rheumatoid arthritis."

Review • Rheumatoid Arthritis

Proof-of-concept study with BMS-817399 to treat moderate to severe rheumatoid arthritis (RA) (clinicaltrials.gov) - P2, N=120; Recruiting; Start date: Sep 2011 -> Feb 2011

Start date • Rheumatoid Arthritis

Lack of efficacy of CCR1 antagonist BMS-817399 in patients with moderate to severe rheumatoid arthritis: Results of 12-week proof-of-concept study (EULAR 2014) - Presentation time: 12.06.2014, 11:45; Abstract #THU0109; P2, N=123; NCT01404585; Sponsor: Bristol-Myers Squibb; "The adjusted mean change (SE) from baseline in DAS28-CRP at 12 weeks was -1.20 (0.18), -1.04 (0.19) and -1.03 (0.19) in the placebo, 200 mg BID and 400 mg BID groups, respectively (adjusted for baseline disease activity and prior use of biologic DMARDs). Similarly, the proportion of ACR 20, 50 and 70 responders at 12 weeks was similar across the treatment groups, independent of prior use of biologic DMARDs."

P2 data • Rheumatoid Arthritis